Litigation
Nov. 6, 2013
Johnson & Johnson subsidiary settles drug marketing case
Johnson & Johnson subsidiary Scios Inc., based in Fremont, resolved claims that it marketed a heart failure drug for uses that were not approved by the Food and Drug Administration and agreed to pay $184 million to the federal government.
By Hadley Robinson
Daily Journal Staff Writer
Johnson & Johnson subsidiary Scios Inc., based in Fremont, resolved claims that it marketed a heart failure drug for uses that were not approved by the Food and Drug Administration and agreed to pay $184 million to the federal government. The announcement Monday came as part of a larger $2.2 billion settlement between Johnson & Johnson and its subsidiaries and the Justice Department for the practice known as off-label marketing.<...
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In